All In Biotech

Drug Trial Radar · NCT03393975

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

52

Actual

Start

Oct 13, 2017

Primary completion

Dec 28, 2023

Study completion May 30, 2024

Sponsor

Lead sponsor
Baxalta now part of ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Jan 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed underneath the skin forming purple bruises or purpura, or from the surface of the skin. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them leading to lower than normal number of red blood cells. A lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in blood clotting, causes TTP. The enzyme breaks up another blood protein called von Willebrand factor that clumps together with platelets to form blood clots. Some people are born with this condition, others get the condition during their life. Many people who born with TTP experience frequent flareups that need to be treated right away. If not treated It can be fatal or cause lasting damage, such as brain damage or a stroke. BAX 930 is a medicine that replaces ADAMTS13 and can prevent or control TTP flareups, called TTP events. The main aim of this study is to compare the number of TTP events in people born with severe TTP when they treated with BAX 930 versus when they are treated with the standard treatment. Treatment will be given in 2 ways: * BAX 930 or standard treatment given to prevent TTP events from happening. * BAX 930 or standard treatment given to control an acute TTP event when it happens, according to the clinic's standard practice. Both BAX 930 and standard treatment are given slowly through a vein (infusion). At the first visit, the study doctor will check if you can participate in the study. If you are eligible and enter the study, you will follow an assigned schedule and either start with BAX 930 (Period 1) and then switch to standard treatment (Period 2) or start with standard treatment (Period 1) and then switch to BAX 930 (Period 2). Everyone will be treated with BAX 930 again for Period 3. Each Period will last approximately 6 months. If you enter the study to control an acute TTP event, you will follow a schedule receiving either BAX 930 or standard care to treat your acute TTP event. Once the acute TTP event has gotten better, you can decide to continue in the study and be given treatment to prevent TTP events from happening, following the schedule above. Another study's aim is to assess side effects from treatment with BAX 930 and standard treatment. To do that, the study doctor will ask you questions about your health at each study visit. The study doctors will also check how long BAX 930 stays in the blood of the participants, over time. They will do this from blood samples taken after participants receive their specific infusions of BAX 930. This will happen at different times during the study. 1 month after all treatment has been completed, participants will visit the clinic for a final check-up.

Conditions

  • Thrombotic Thrombocytopenic Purpura (TTP)

Interventions

  • TAK-755Biological

    Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg TAK-755 ORT during Period 1 and Period 2 and switch to TAK-755 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of TAK-755.

  • Standard of careBiological

    Participants will receive Investigator-recommended Standard of care (SoC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic TreatmentTime frame: Up to 74.5 months

Locations

33 sites in 9 countries. Site status is shown where the registry gives one.

  • Winship Cancer Institute

    Atlanta, Georgia

  • Alliance for Childhood Diseases, Cure 4 the Kids Foundation

    Las Vegas, Nevada

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Ohio State Univ College Of Medicine

    Columbus, Ohio

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • The Methodist Hospital

    Houston, Texas

  • AKH - Medizinische Universität Wien

    Vienna, Austria

  • Hôpital Robert Debré - Paris

    Paris, France

  • Hopital Claude Huriez - CHU Lille

    Lille, Nord, France

  • Hôpital Necker - Enfants Malades

    Paris, Paris, France

  • Hôpital Saint-Antoine

    Paris, Paris, France

  • CHU Saint Etienne - Hôpital Nord

    Saint-Priest-en-Jarez Cedex, Pays de la Loire Region, France

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Jena

    Jena, Thuringia, Germany

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

    Bergamo, Italy

  • Azienda Ospedaliera Universitaria "Policlinico - Vittorio Emanuele" (Presidio Ferrarotto Alessi)

    Catania, Italy

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Dipartimento di Medicina Traslazionale e di Precisione - "Sapienza" Universita di Roma

    Rome, Italy

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • Hyogo College of Medicine Hospital

    Nishinomiya-shi, Hyōgo, Japan

  • Medical Hospital, Tokyo Medical and Dental University

    Bunkyō City, Tokyo-To, Japan

  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny

    Warsaw, Poland

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, La Coruña, Spain

  • Hospital de Cruces

    Barakaldo, Vizcaya, Spain

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • University College London Hospitals

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.